Codexis, Inc. (CDXS) company profile
Close on Nov 17, 2026Market cap $117.17MP/E –Yield –
About Codexis
Industrial Organic Chemicals, SIC 2860
Codexis, Inc. discovers, engineers, and supplies specialized enzymes and proteins to optimize the manufacturing of biopharmaceutical therapeutics. The company operates through two primary areas: its small molecule biocatalysis business and its ECO Synthesis platform. In biocatalysis, it designs custom enzymes that act as biocatalysts to improve synthesis efficiency, product purity, and yield for small-molecule drugs. Through its ECO Synthesis platform, the company provides enzymatic synthesis tools and contract process development services to support the production of RNA interference therapies, including small interfering RNA. Its customers include global pharmaceutical developers, biotechnology firms, and contract development and manufacturing organizations.
The company is headquartered in Redwood City, California, where it conducts research, development, and small-scale manufacturing at its innovation laboratory. Codexis also holds a facility lease in Hayward, California. Its enzyme products support eighteen commercially approved drugs and fifteen clinical-stage candidates. External commercial manufacturing takes place through third-party partners situated in Austria, Italy, and the United Kingdom.
Summary of the business section of Codexis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Codexis, Inc.
- Founded
- 2002
- Headquarters
- Redwood City, CA
- Address
- 200 Penobscot Drive 94063
- Phone
- (650) 421-8100
- Website
- www.codexis.com
- Employees
- 146, Dec 31, 2025
- Industry
- Industrial Organic Chemicals
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, CA
Stock & identifiers
- Ticker
- CDXS
- Exchange
- Nasdaq
- IPO date
- Apr 22, 2010
- Shares outstanding
- 110M, Aug 6, 2026
- Public float
- $133.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1200375
- CUSIP
- 192005106
- ISIN
- US1920051067
- FIGI
- BBG000RN0GZ5
- Share class FIGI
- BBG001SV4129
- LEI
- 549300KGLM6CDPTVSE20
- EIN
- 71-0872999
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alison Moore | President and CEO, Director | 244,171 |
| Georgia Erbez | See Remarks | 60,475 |
| Stefan Lutz | Chief Scientific Officer | 130,421 |
| Kevin Norrett | Chief Operating Officer | 177,327 |
| Vre Raymond De | Director | 83,723 |
| Cynthia Collins | Director | 112,157 |
| Esther Martinborough | Director | 129,036 |
| Christos Richards | Director | 85,133 |
| Rahul Singhvi | Director | 137,052 |
| H. Stewart Parker | Director | 143,583 |
| Stephen George Dilly | Director | 727,053 |
| David V. Smith | Director | 194,275 |
| Dennis P. Wolf | Director | 138,951 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Alison Moore | $2.32M | $920.92K | $1.27M | $35 | – |
| FY2025 Stephen Dilly | $2.19M | -$789.80K | $1.27M | $35 | – |
| FY2024 | $3.47M | $6.21M | $1.31M | $102 | – |
| FY2023 | $3.12M | $1.23M | $1.94M | $65 | – |
| FY2022 John J.Nicols | $3.42M | -$3.86M | $1.93M | $15 | – |
| FY2022 John Nicols | $3.42M | -$3.86M | $1.93M | $15 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Alison Moore President and Chief Executive Officer | $524.73K | $255.99K | $1.07M | $463.13K | $14.21K | $2.32M | +111% |
| Georgia Erbez Chief Financial Officer and Chief Business Officer | $507.42K | $117.44K | $487.52K | $237.50K | $1.04K | $1.35M | +45% |
| Stefan Lutz Chief Scientific Officer | $481.57K | $76.48K | $317.46K | $232.75K | $14.84K | $1.12M | – |
| Stephen G. Dilly Executive Chair of the Board of Directors and former President and Chief Executive Officer | $758.90K | $374.95K | $489.69K | $521.05K | $50.01K | $2.19M | -37% |
| Kevin Norrett Former Chief Operating Officer | $501.30K | $57.31K | $10.58K | $250.00K | $514.72K | $1.33M | -12% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 146 full-time employees and part-time employees worldwide.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 6, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 2, 2013 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 9, 2013 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 18, 2013 | Late filing | Notification of late filing |
| Sep 4, 2012 | Listing | Registration of securities on an exchange (Form 8-A) |
| Oct 28, 2010 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 19, 2010 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?